LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

Pharmaceutical giant Novo Nordisk (NYSE ... which target diabetes and obesity, respectively. In one head-to-head study, Zepbound even proved superior to Wegovy in helping patients shed excess ...

Novo Nordisk (NYSE:NVO) A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy more than ... the drugmaker’s head of U.S. operations and global business development, noting that the GLP-1 med has reached about ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...

Novo Nordisk is by far the leader in the GLP-1 drug market. The company's pipeline in this area is also very deep. The Danish drugmaker is also looking to diversify its lineup. Novo Nordisk's work ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

Novo Nordisk (NVO) remains a dominant force in diabetes and obesity treatments, yet the stock is currently trading below its fair value. Despite a recent decline following disappointing trial ...

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the increasingly ...

with lots of momentum in Obesity Care, and its market share stayed relatively steady. At the current valuation, Novo Nordisk stock is attractive, with a forward PEG ratio of 0.91x and earnings set ...

Novo Nordisk (NYSE: NVO) stock is in a funk ... the downside," with the analyst worrying about "dynamics" in the U.S. obesity market. Lucky for Novo stock, though, obesity may not be the only ...